The ECU Health Medical Center is expanding heart care with two new technologies for transcatheter tricuspid valve replacement. The new technologies are EVOQUE™, a ...

Where this device will fit in with other emerging options remains to be seen, but it might hold an advantage in large annuli.

Two state-of-the-art new technologies for transcatheter tricuspid valve replacements is expanding advanced heart care with ...

Inc. (Stock Code: 2500.HK, hereinafter referred to as 'Venus Medtech' or the 'Company'), a global leader in structural heart therapies, has announced financial results for the year ended December 31, ...

Adhering to the principles of evidence-based medicine, Venus Medtech has consistently conducted long-term follow-up studies ...

LuX-Valve TTVR was performed via the transatrial approach, resulting in a procedural success rate of 97.6%, with one patient ...

As was the case with the recent final national coverage determination (NCD) for transcatheter tricuspid valve replacement (TTVR), CMS is proposing that reimbursement for T-TEER only be provided under ...

In brief: Valve has just posted the results of March's Steam survey, and, as predicted, things have returned to normal after the weirdness we saw during the previous month. This means there's a ...

The primary endpoint was a composite of all-cause mortality or tricuspid valve surgery, heart failure hospitalizations, and quality-of-life improvement measured by the KCCQ score. TriClip is approved ...

system to treat tricuspid regurgitation (TR), or a leaky heart valve, offers substantial and sustained improvements in the severity of TR after two years. The results also demonstrate the TriClip ...